SCHEMBL4300368

SCHEMBL4300368

O=C1C(O)=C(c2ccc(O)cc2)C(c2c[nH]c3ccccc23)N1CCCn1ccnc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
RXFP1 Q9HBX9 2/20 0.45
ANXA2 P07355 1/20 0.45
S100A10 P60903 1/20 0.45
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
QPCT Q16769 2/20 0.43
GSK3B P49841 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TP53 P04637 6/20 0.43
MDM2 Q00987 6/20 0.43
IDE P14735 1/20 0.43
CYP19A1 P11511 1/20 0.41
TBXAS1 P24557 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4303876 0.95 RXFP1 (0.48) KDM4ERXFP1ANXA2S100A10KMT2A
SCHEMBL4292231 0.91 KDM4E (0.43) KDM4ERXFP1ANXA2S100A10KMT2A
SCHEMBL4300546 0.90 QPCT (0.49) KDM4ERXFP1ANXA2S100A10KMT2A
SCHEMBL4293364 0.88 KDM4E (0.51) KDM4ERXFP1ANXA2S100A10KMT2A
SCHEMBL4298706 0.85 KDM4E (0.52) KDM4ERXFP1ANXA2S100A10KMT2A
SCHEMBL4293474 0.85 KDM4E (0.52) KDM4ERXFP1ANXA2S100A10KMT2A
SCHEMBL4297741 0.85 KDM4E (0.51) KDM4ERXFP1ANXA2S100A10KMT2A
SCHEMBL4291068 0.84 KDM4E (0.50) KDM4ERXFP1ANXA2S100A10KMT2A
SCHEMBL4296940 0.84 KDM4E (0.48) KDM4ERXFP1ANXA2S100A10KMT2A
SCHEMBL4293425 0.83 KDM4E (0.49) KDM4ERXFP1ANXA2S100A10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US claimed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US claimed
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US disclosed
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL KDM4E 2532/4885RXFP1 1183/4885ANXA2 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.